HK Stock Market Move | CLOUDBREAK-B(02592) is currently trading up over 4%. Its subsidiary will discuss the R&D matters of CBT-004 with the US FDA.

CLOUDBREAK-B (02592) rose more than 4%, as of the time of publication, up 4.13% to HK$8.58, with a turnover of HK$11.8243 million. On the news front, Bocangshiyun previously announced that its wholly-owned subsidiary Cloudbreak USA registered in California, USA, has scheduled a meeting with the US Food and Drug Administration on December 10, 2025, after the completion of the Phase 2 clinical trial of the Group's candidate drug CBT-004. This Phase 2 clinical trial post-meeting is an important milestone in the development process of CBT-004, discussing potential Phase 3 clinical trial development and related requirements for new drug applications.